Integrated BioPharma Reports Financial Results for Q1 and Fiscal Year Ended June 30, 2026
Integrated BioPharma, Inc. reported a significant YoY revenue decrease of 19.3% for the fiscal year ended June 30, 2026, primarily driven by reliance on high-concentration customers in its Contract Manufacturing Segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed